Author pages are created from data sourced from our academic publisher partnerships and public sources.
Share This Author
Nomenclature Revision for Encapsulated Follicular Variant of Papillary Thyroid Carcinoma: A Paradigm Shift to Reduce Overtreatment of Indolent Tumors.
Thyroid tumors currently diagnosed as noninvasive EFVPTC have a very low risk of adverse outcome and should be termed NIFTP, and this reclassification will affect a large population of patients worldwide and result in a significant reduction in psychological and clinical consequences associated with the diagnosis of cancer.
Genomic and transcriptomic hallmarks of poorly differentiated and anaplastic thyroid cancers.
- I. Landa, T. Ibrahimpašić, +14 authors J. Fagin
- Biology, MedicineThe Journal of clinical investigation
- 1 March 2016
These data support a model of tumorigenesis whereby PDTCs and ATCs arise from well-differentiated tumors through the accumulation of key additional genetic abnormalities, many of which have prognostic and possible therapeutic relevance.
Integrated Genomic Characterization of Papillary Thyroid Carcinoma
The genomic landscape of 496 PTCs is described and a reclassification of thyroid cancers into molecular subtypes that better reflect their underlying signaling and differentiation properties is proposed, which has the potential to improve their pathological classification and better inform the management of the disease.
Comprehensive Characterization of Cancer Driver Genes and Mutations
This study reports a PanCancer and PanSoftware analysis spanning 9,423 tumor exomes (comprising all 33 of The Cancer Genome Atlas projects) and using 26 computational tools to catalog driver genes and mutations, identifying 299 driver genes with implications regarding their anatomical sites and cancer/cell types.
Frequent somatic TERT promoter mutations in thyroid cancer: higher prevalence in advanced forms of the disease.
- I. Landa, I. Ganly, +5 authors J. Fagin
- Biology, MedicineThe Journal of clinical endocrinology and…
- 5 July 2013
TERT promoter mutations are highly prevalent in advanced thyroid cancers, particularly those harboring BRAF or RAS mutations, whereas PTCs with BRAF/RAS mutations are most often TERT promoter wild type.
Mutational profile of advanced primary and metastatic radioactive iodine-refractory thyroid cancers reveals distinct pathogenetic roles for BRAF, PIK3CA, and AKT1.
An assay panel for mass spectrometry genotyping encompassing the most significant oncogenes in this disease encompassing 111 mutations in RET, BRAF, NRAS, HRAS, KRAS, PIK3CA, AKT1, and other related genes was designed to obtain comprehensive genetic information on advanced thyroid cancers.
Relief of feedback inhibition of HER3 transcription by RAF and MEK inhibitors attenuates their antitumor effects in BRAF-mutant thyroid carcinomas.
The HER kinase inhibitor lapatinib prevents MAPK rebound and sensitizes BRAF-mutant thyroid cancer cells to RAF or MAP-ERK kinase inhibitors, providing a rationale for combining ERK pathway antagonists with inhibitors of feedback-reactivated HER signaling in this disease.
Molecular genotyping of papillary thyroid carcinoma follicular variant according to its histological subtypes (encapsulated vs infiltrative) reveals distinct BRAF and RAS mutation patterns
- M. Rivera, J. Ricarte-Filho, +4 authors R. Ghossein
- Biology, MedicineModern Pathology
- 1 September 2010
The follicular variant of papillary thyroid carcinoma was shown to be close to the follicular adenoma/carcinoma group of tumors with a high RAS and very low BRAF mutation rates, and infiltrative follicular variants had a much higher frequency of extrathyroid extension, positive margins and nodal metastases than encapsulated tumors.
Oncogenic Signaling Pathways in The Cancer Genome Atlas
This work charted the detailed landscape of pathway alterations in 33 cancer types, stratified into 64 subtypes, and identified patterns of co-occurrence and mutual exclusivity.
Solitary fibrous tumors of the head and neck: a clinicopathologic and radiologic review.
- I. Ganly, Snehal G. Patel, +5 authors J. Shah
- MedicineArchives of otolaryngology--head & neck surgery
- 1 May 2006
Solitary fibrous tumors of the head and neck region are rare and most commonly benign, but patients with these tumors can be safely treated with local excision, but tumors with positive margins require close follow-up over several years owing to the potential for late local recurrence.